# APMD catalysts: Apnimed, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/apmd/catalysts

> Apnimed, Inc. (APMD) has 1 upcoming catalyst. The next is the Strattera (atomoxetine) PDUFA date, February 28, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for APMD?

Apnimed, Inc. (APMD) has 1 upcoming catalyst. The next is the Strattera (atomoxetine) PDUFA date, February 28, 2027. Press release filed with the SEC (EX-99): "U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi, and assigned a PDUFA target action date of February 28, 2027" [Calendar and source filings](https://sec-api.dev/companies/apmd/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-385355, https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-09-08. Cite: https://sec-api.dev/companies/apmd/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Apnimed, Inc. |
| Ticker | APMD (Nasdaq) |
| SEC CIK | 1745648 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/apmd |

## Cash runway

Cash $172.8M as of 2026-06-30; quarterly burn $19.1M; about 27.1 months of runway at that rate (XBRL company facts, accession 0001193125-26-385356).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 7, 2025 | [AD109 primary completion](https://sec-api.dev/pdufa/ad109) | APMD | OSA | completed | "NCT05811247 (Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Apnimed; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05811247)) |
| June 2026 | [Aroxybutynin and atomoxetine primary completion](https://sec-api.dev/pdufa/aroxybutynin-and-atomoxetine) | APMD | OSA | delayed | "NCT06566820 (Continuation Protocol for Obstructive Sleep Apnea (OSA)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Apnimed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06566820)) |
| September 8, 2026 | [Apnimed, Inc. earnings report](https://sec-api.dev/companies/apmd/catalysts) | APMD |  | completed | "Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm)) |
| September 8, 2026 | [Strattera (atomoxetine) NDA/BLA acceptance](https://sec-api.dev/pdufa/atomoxetine) | APMD | with obstructive sleep apnea | completed | "Announced the FDA accepted for review the New Drug Application ("NDA") for AD109 (proposed proprietary name Oxnimbi) for the treatment of adults with obstructive sleep apnea ("OSA")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm)) |
| November 3, 2026 | [AD109 topline data readout](https://sec-api.dev/pdufa/ad109) | APMD | OSA | completed | "NCT05811247 (Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Apnimed; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05811247?tab=results)) |
| February 28, 2027 | [Strattera (atomoxetine) PDUFA date](https://sec-api.dev/pdufa/atomoxetine) | APMD |  | scheduled | "U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi, and assigned a PDUFA target action date of February 28, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm)) |

## Drugs

- [AD109](https://sec-api.dev/pdufa/ad109): OSA
- [Aroxybutynin and atomoxetine](https://sec-api.dev/pdufa/aroxybutynin-and-atomoxetine): OSA
- [Strattera (atomoxetine)](https://sec-api.dev/pdufa/atomoxetine): with obstructive sleep apnea

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/apmd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "APMD catalysts: Apnimed, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/apmd/catalysts

```bibtex
@misc{secapidev_companies_apmd_catalysts_20261116,
  title        = {APMD catalysts: Apnimed, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/apmd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_apmd_catalysts_20261116","title":"APMD catalysts: Apnimed, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/apmd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
